The primary aim of this review is to provide practical recommendations in terms of fractionation, dose, constraints and selection criteria to be used in the daily clinical routine. Based on the analysis of the literature reviewed, in order to keep the risk of severe side effects ≤3,5%, patients should be stratified according to the target volume. Thus, patients should be treated with different fractionation and total EQD2 (<12.5 ml: EQD2 < 65 Gy with radiosurgery; >12.5 ml and <35 ml: EQD2 < 50 Gy with hypofractionated stereotactic radiotherapy; >35 ml and <50 ml: EQD2 < 36 Gy with conventionally fractionated radiotherapy). Concurrent approaches with temozolomide or bevacizumab do not seem to improve the outcomes of reirradiation and may lead to a higher risk of toxicity but these findings need to be confirmed in prospective series.

Re-irradiation as salvage treatment in recurrent glioblastoma: A comprehensive literature review to provide practical answers to frequently asked questions / Scoccianti, Silvia*; Francolini, Giulio; Carta, Giulio Alberto; Greto, Daniela; Detti, Beatrice; Simontacchi, Gabriele; Visani, Luca; Baki, Muhammed; Poggesi, Linda; Bonomo, Pierluigi; Mangoni, Monica; Desideri, Isacco; Pallotta, Stefania; Livi, Lorenzo. - In: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. - ISSN 1040-8428. - ELETTRONICO. - 126:(2018), pp. 80-91. [10.1016/j.critrevonc.2018.03.024]

Re-irradiation as salvage treatment in recurrent glioblastoma: A comprehensive literature review to provide practical answers to frequently asked questions

Scoccianti, Silvia;Francolini, Giulio;Carta, Giulio Alberto;Greto, Daniela;Simontacchi, Gabriele;Visani, Luca;Baki, Muhammed;Poggesi, Linda;Bonomo, Pierluigi;Mangoni, Monica;Desideri, Isacco;Pallotta, Stefania;Livi, Lorenzo
2018

Abstract

The primary aim of this review is to provide practical recommendations in terms of fractionation, dose, constraints and selection criteria to be used in the daily clinical routine. Based on the analysis of the literature reviewed, in order to keep the risk of severe side effects ≤3,5%, patients should be stratified according to the target volume. Thus, patients should be treated with different fractionation and total EQD2 (<12.5 ml: EQD2 < 65 Gy with radiosurgery; >12.5 ml and <35 ml: EQD2 < 50 Gy with hypofractionated stereotactic radiotherapy; >35 ml and <50 ml: EQD2 < 36 Gy with conventionally fractionated radiotherapy). Concurrent approaches with temozolomide or bevacizumab do not seem to improve the outcomes of reirradiation and may lead to a higher risk of toxicity but these findings need to be confirmed in prospective series.
2018
126
80
91
Scoccianti, Silvia*; Francolini, Giulio; Carta, Giulio Alberto; Greto, Daniela; Detti, Beatrice; Simontacchi, Gabriele; Visani, Luca; Baki, Muhammed; Poggesi, Linda; Bonomo, Pierluigi; Mangoni, Monica; Desideri, Isacco; Pallotta, Stefania; Livi, Lorenzo
File in questo prodotto:
File Dimensione Formato  
reirr.pdf

Accesso chiuso

Tipologia: Pdf editoriale (Version of record)
Licenza: Tutti i diritti riservati
Dimensione 328.98 kB
Formato Adobe PDF
328.98 kB Adobe PDF   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1134487
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 43
  • ???jsp.display-item.citation.isi??? 40
social impact